Baird on Fate Therapeutics (FATE): 'Incrementally positive on FT819 enrollment ramp and early FT836 clinical data'
Tweet Send to a Friend
Baird analyst Jack Allen reiterated a Neutral rating and $4.00 price target on Fate Therapeutics (NASDAQ: FATE).The analyst comments "Incrementally ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
